Selecta Biosciences, Inc. (NASDAQ:SELB) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET

Company Participants

Kevin Tan – Chief Financial Officer

Carsten Brunn – President and Chief Executive Officer

Peter Traber – Chief Medical Officer

Kei Kishimoto – Chief Scientific Officer

Conference Call Participants

Kristen Kluska – Cantor Fitzgerald

Yun Zhong – BTIG

Yatin Suneja – Guggenheim Partners

John Newman – Canaccord

Raju Prasad – William Blair

Boobalan Pachaiyappan – H.C. Wainwright

Operator

Good day, and welcome to the Selecta Bio Second Quarter 2022 Earnings Release Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Kevin Tan, Chief Financial Officer of Selecta Bio. Please go ahead.

Kevin Tan

Thank you, and good morning. Welcome to our second quarter 2022 financial results and corporate update conference call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website, worldwide web selectabio.com, and our quarterly report on Form 10-Q for the quarter ended June 30, 2022, which we intend to file in the coming days with the Securities and Exchange Commission, or SEC. Joining me today are Carsten Brunn, President and Chief Executive Officer; Peter Traber, Chief Medical Officer; and Kei Kishimoto, Chief Scientific Officer.

During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy, regulatory and clinical progress of our product candidates, our financial projections and our future expectations, plans, partnerships and prospects. These statements are subject to various risks that are described in the filings made with the SEC including our most recent annual report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, August 4, 2022, and Selecta disclaims any obligation to update such statements except as required by law even if management's views change.

I would now like to turn the call over to Carsten Brunn. Carsten?

Carsten Brunn

Thank you, Kevin. Good morning. I appreciate everyone taking the time to join us today. In the second quarter of 2022, we made steady progress across our proprietary pipeline and achieved numerous key milestones. Most notably, on June 29, we completed the enrollment of the DISSOLVE II trial, triggering a $10 million milestone payment obligation from Sobi. Our partners continue to progress the ImmTOR platform in combination with their gene therapy candidates.